Effect of Thiazolidinedione Treatment Vascular Risk Markers

Completed · Phase 4

Conditions studied: Diabetes Mellitus, Type 2, Vascular Diseases

In brief

The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.

Key facts

Study ID

NCT00571506

Run by

University of Arkansas

People needed

25

Starts

2004-05-01

Expected to finish

2007-08-01

Last updated by the study team

2009-12-09

Who can join

Age: 40 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women of all races
• Age 40-65 years
• Diagnosis of type 2 diabetes
• hemoglobin A1C ≥ 7%
• eligible whether or not currently taking antihyperglycemic medications

You may not qualify if…

• History of rosiglitazone or pioglitazone use in the previous 3 months
• Known diagnosis of peripheral vascular disease or cardiac failure
• Recent history (within past 6 months) of ischemic stroke, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass surgery
• Active liver disease or elevated serum transaminases (ALT >2.5x upper limit of normal)
• Current therapy with oral anticoagulants (warfarin, heparin, low molecular weight heparin), clopidogrel, or immunosuppressive agents
• Pregnancy or breastfeeding
• Any other condition, in the opinion of the investigator, that renders the subject unable to complete the study, that interferes with optimal participation in the study, or that produces significant risk to the subject

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.